Journal Article

Thromboxane–prostaglandin receptor antagonist, terutroban, prevents neurovascular events after subarachnoid haemorrhage: a nanoSPECT study in rats

Velly, Lionel J., Giacomino, Laura, Alessi, Marie-Christine, Guillet, Benjamin, Lagier, David, Tonon, David, Garrigue, Philippe, Bruder, Nicolas, Martin, Jean-Charles

2019

Overview

Background Several lipid metabolites in cerebrospinal fluid are correlated with poor outcomes in aneurysmal subarachnoid haemorrhage. Most of these metabolites bind to ubiquitous thromboxane–prostaglandin (TP) receptors, causing vasoconstriction and inflammation. Here, we evaluated terutroban (TBN), a specific TP receptor antagonist, for the prevention of post-haemorrhage blood-brain barrier disruption, neuronal apoptosis and delayed cerebral hypoperfusion. Methods The rat double subarachnoid haemorrhage model was produced by twice injecting (days 1 and 2) autologous blood into the cisterna magna. Seventy-eight male Sprague-Dawley rats were assigned to experimental groups. Rats exposed to subarachnoid haemorrhage were allocated to no treatment (SAH group) or TBN treatment by gastric gavage during the first 5 days after haemorrhage (SAH+TBN group). Control rats received artificial cerebrospinal fluid injections (CSF group). Sham-operated rats with or without TBN administration were also studied. Body weight and Garcia neurological scores were assessed on day 2 and day 5. We used nanoscale single-photon emission computed tomography (nanoSPECT) to measure brain uptake of three radiolabelled agents: 99m Technetium-diethylenetriaminepentacetate ( 99m Tc-DTPA), which indicated blood-brain barrier permeability on day 3, 99m Technetium-annexin V-128 ( 99m Tc-Anx-V128), which indicated apoptosis on day 4, and 99m Technetium-hexamethylpropyleneamineoxime ( 99m Tc-HMPAO), which indicated cerebral perfusion on day 5. Basilar artery narrowing was verified histologically, and cerebral TP receptor agonists were quantified. Results 99m Tc-DTPA uptake unveiled blood-brain barrier disruption in the SAH group. TBN mitigated this disruption in the brainstem area. 99m Tc-Anx-V128 uptake was increased in the SAH group and TBN diminished this effect in the cerebellum. 99m Tc-HMPAO uptake revealed a global decreased perfusion on day 5 in the SAH group that was significantly counteracted by TBN. TBN also mitigated basilar artery vasoconstriction, neurological deficits (on day 2), body weight loss (on day 5) and cerebral production of vasoconstrictors such as Thromboxane B2 and Prostaglandin F2α. Conclusions Based on in vivo nanoscale imaging, we demonstrated that TBN protected against blood-brain barrier disruption, exerted an anti-apoptotic effect and improved cerebral perfusion. Thus, TP receptor antagonists showed promising results in treating post-haemorrhage neurovascular events.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Apoptosis / Blood brain barrier / Body weight / Brain / CAT scans / Cerebral vasospasm / Complications and side effects / Critical Care Medicine / Dosage and administration / Drug therapy / Emergency Medicine / Human health and pathology / Inflammation / Intensive / Life Sciences / Medicine / Medicine & Public Health / Metabolites / Neurons / Neurovascular diseases / Patient outcomes / Permeability / Platelet aggregation inhibitors / Prevention / Prostaglandins / Risk factors / Single photon emission computed tomography / Single-photon emission computerized tomography / Subarachnoid haemorrhage / Subarachnoid hemorrhage / Thromboxane–prostaglandin receptor / Tomography / Transient ischemic attack / Vasoconstriction